Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
Administration Guidelines
Injection Sites
- Abdomen (2 inches from navel)
- Front of thighs
- Back of upper arms
Rotation Schedule
- Use a different area each week
- Keep a rotation log
- Avoid areas with scars, bruises, or irritation
Timing
- Same day each week, with or without food
- Peak concentration: 24 hours after injection
- Half-life: ~184 hours (7.7 days)
Administration Guidelines
Injection Sites
Subcutaneous injection sites include:
- Abdomen (2 inches from navel)
- Front of thighs
- Back of upper arms
Rotation Schedule
- Use a different area each week
- Keep a rotation log
- Avoid areas with scars, bruises, or irritation
Timing
- Once-weekly subcutaneous injection
- Same day each week, with or without food
- Rotate injection sites (abdomen, thigh, upper arm)
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.